This year we launched Immunotherapy Advances, our first fully Open Access journal. It covers the translational pipeline for immunotherapy from discovery research and preclinical animal models through to clinical trials.
The Founding Editor-in-Chief, Professor Tim Elliott, and the Editorial team of globally renowned experts, have been working hard to launch the inaugural issue in December 2020. This article provides a snapshot of these brilliant Regional Editors, looking into their areas of expertise, career roadmap and the type of research they hope to see in Immunotherapy Advances.
Find out more